MAST4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tp-030N (SCHEMBL20477267)	1.00	3/20
Tp-030-1 (SCHEMBL20477342)	1.00	3/20
SCHEMBL20477276	0.91	3/20
SCHEMBL20477283	0.88	3/20
SCHEMBL20477343	0.87	3/20
SCHEMBL20477351	0.87	3/20
SCHEMBL20477265	0.86	3/20
SCHEMBL20477413	0.86	3/20
SCHEMBL20477411	0.85	3/20
SCHEMBL20477231	0.84	3/20
SCHEMBL20477363	0.84	3/20
SCHEMBL20477237	0.84	3/20
SCHEMBL20477418	0.84	3/20
SCHEMBL20477427	0.84	3/20
SCHEMBL20477279	0.83	3/20
SCHEMBL20477292	0.83	3/20
SCHEMBL20477297	0.83	3/20
SCHEMBL20477274	0.81	3/20
SCHEMBL20477441	0.81	3/20
SCHEMBL20477459	0.81	3/20

Clinical trials — most relevant to MAST4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis	PHASE3	COMPLETED
Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)	PHASE2/PHASE3	COMPLETED
Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients	PHASE2/PHASE3	UNKNOWN
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients	PHASE3	RECRUITING
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis	PHASE3	COMPLETED
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis	PHASE2	COMPLETED
Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations	PHASE2	COMPLETED
EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions	PHASE2	COMPLETED
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)	PHASE1/PHASE2	NOT_YET_RECRUITING
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies	PHASE1	COMPLETED
Allergy and Immunology Natural History Study	nan	RECRUITING
Cause and Natural Course of Pediatric-Onset Mastocytosis	nan	COMPLETED
Cause of Unexplained Anaphylaxis	nan	ACTIVE_NOT_RECRUITING
Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations	nan	COMPLETED
Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals	nan	COMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers.	nan	RECRUITING
Pathogenesis of Physical Induced Urticarial Syndromes	nan	COMPLETED
T Cell Cytokine Changes During IL-4 Receptor Treatment for Asthma	nan	COMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Susceptibility Genes in Autism Spectrum Disorders	nan	COMPLETED
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing	nan	COMPLETED
Chromosome 5Q Gene Variants and Asthma-Related Traits	nan	COMPLETED
Exploring the Genetics of Neuropathic Pain	nan	RECRUITING
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease	nan	UNKNOWN
In Vivo Assessment of Histamine Pharmacodynamics	nan	WITHDRAWN
Study of Factors Regulating Mast Cell Proliferation	nan	RECRUITING
Autophagy Bladder Cancer	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MAST4 binder may also engage these)

Protein	Name	Similarity
Q811L6	—	1.000	Q811L6 →
Q6P0Q8	—	1.000	Q6P0Q8 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.997	landscape →
Q60700	—	0.997	Q60700 →
Q76I79	—	0.997	Q76I79 →
A7MBB4	—	0.996	A7MBB4 →
Q924U5	—	0.996	Q924U5 →
Q5R8X7	—	0.996	Q5R8X7 →
Q9R1L5	—	0.995	Q9R1L5 →
MAST3	Microtubule-associated serine/threonine-protein kinase 3	0.995	landscape →
Q60592	—	0.995	Q60592 →
Q3U214	—	0.995	Q3U214 →
Q2PFD7	—	0.995	Q2PFD7 →
Q63553	—	0.994	Q63553 →
Q810W7	—	0.994	Q810W7 →
Q9UPV7	—	0.994	Q9UPV7 →
Q9H329	—	0.994	Q9H329 →
Q9BQK8	—	0.994	Q9BQK8 →
Q641K5	—	0.994	Q641K5 →
A2AHC3	—	0.994	A2AHC3 →
Q9P1A6	—	0.993	Q9P1A6 →
O43182	—	0.993	O43182 →
Q8VDU5	—	0.993	Q8VDU5 →
P19091	—	0.993	P19091 →
Q3ULB5	—	0.993	Q3ULB5 →
Q60610	—	0.993	Q60610 →
Q6NN85	—	0.993	Q6NN85 →
O14512	—	0.993	O14512 →
Q99PI5	—	0.993	Q99PI5 →
P56931	—	0.992	P56931 →